Could a schizophrenia drug curb Cocaine's grip?
NCT ID NCT07624227
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial investigates whether Cobenfy, a medication typically used for schizophrenia, can reduce the rewarding effects of cocaine in people with cocaine use disorder. Over an 11-day inpatient stay, participants receive either Cobenfy or a placebo twice daily, then take part in sessions where they can choose between cocaine and money. The study aims to see if Cobenfy makes cocaine less appealing and to check the safety of combining the two drugs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cobenfy (xanomeline + trospium)
- What this could lead to
- If successful, Cobenfy could become a medication to help people with cocaine use disorder reduce their cocaine use by blocking its rewarding effects.
- What could go wrong
- This is an early-phase trial with only 32 participants, so results may not apply broadly. Combining Cobenfy with cocaine may cause unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COCAINE USE DISORDER (CUD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Psychopharmacology of Addiction Laboratory
Lexington, Kentucky, 40502, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.